Compare Cytokinetics Inc (CYTK) vs Newegg Commerce Inc (NEGG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Newegg Commerce Inc — how do they compare? Cytokinetics Inc trades at $76.67 (market cap $10.63B), while Newegg Commerce Inc trades at $19.76 (market cap $398.29M). The key difference: Cytokinetics Inc is far larger — about 26.7× Newegg Commerce Inc's market cap, and Cytokinetics Inc is trading nearer its 52-week high, Newegg Commerce Inc nearer its low. Which is the better fit depends on your goals.
| CYTK | NEGG | |
|---|---|---|
Market Cap | $10.63B | $398.29M |
Sector | Technology | Consumer Cyclical |
52-Week High | $87.26 | $128.09 |
52-Week Low | $34.31 | $12.87 |
Enterprise Value | $10.74B | $397.09M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $75.64, down 2.39% on the day, amid a bearish technical signal despite a Q2 2026 earnings beat. The stock shows negative profitability with a net income margin of -1,321.12% and a high P/S ratio of 140.65, reflecting significant losses and premium valuation relative to sales. Recent news highlights strong uptake of MYQORZO and UK regulatory approval, supporting commercial momentum.
The outlook is polarized: analyst consensus is strongly bullish with a $111.14 price target, but high cash burn and competitive pressures pose risks. Investment opportunity hinges on MYQORZO's market expansion, while execution and funding needs remain key challenges for shareholders.
Newegg Commerce (NEGG) trades at $19.80, up 7.73% with bullish technical signals and strong recent earnings beats. The stock shows improving fundamentals with revenue stabilizing around $1.4B and net income turning positive in 2026 forecasts. Recent business developments include AI shopping enhancements and exclusive product launches driving growth potential.
Outlook remains cautiously optimistic with improving profitability but carries execution risks. The high P/E ratio of 73.16 suggests premium valuation requiring sustained growth. Key opportunities include technology sector recovery and AI initiatives, while risks involve competitive pressures and cash flow volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Newegg Commerce Inc
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home and gaming products and provides certain third-party logistics services globally.
Read more on NEGG →
